Oncolytics Biotech Inc. (ONCY) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Calgary, AB, カナダ. 現CEOは Jared Kelly.
ONCY を有する IPO日 2001-10-05, 28 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $110.4M.
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
